Director, Translational Sciences

UPMC Presbyterian Shadyside seeks multiple Directors, Translational Sciences in Pittsburgh, PA to develop, manage, and direct UPMC Enterprises' strategic investment portfolio and start-up incubator by leading the group's efforts to evaluate the proposals for new investments and commercialize scientific discoveries in the fields of oncology, autoimmune diseases, and the central nervous systems into new life-science start-ups. Responsible for evaluating investment proposals and developing detailed project plans, timelines, and budgets in order to translate scientific discoveries into innovative medical devices, therapies, and medications for FDA approval, licensing, or acquisition. Provide direct support for the current portfolio of strategic investment companies, focusing on the financial monitoring, budgeting, and forecasting of Novasenta, BlueSphere Bio, Avista Health, Generian, as well as other newly formed therapeutic start-ups. 'Own' the entire investment process, from proactively sourcing new investment opportunities and performing 'landscape' analysis, initial screening, final investment, and post-investment monitoring and support. Develop financial return models and perform quantitative and return analysis of companies' potential commercial pipelines in order to properly evaluate project funding proposals from UPMC and University of Pittsburgh Investigators, as well as external funding requests. Assess the needs of each investment project to ensure provision of UPMC's clinical, legal, and financial expertise and resources needed to ensure an efficient transition between research and clinical development.

Job Responsibilities: (please list specific job responsibilities)

• Develop, manage, and direct UPMC Enterprises' strategic investment portfolio and start-up incubator by leading the group's efforts to evaluate the proposals for new investments and commercialize scientific discoveries in the fields of oncology, autoimmune diseases, and the central nervous systems into new life-science start-ups.

• Responsible for evaluating investment proposals and developing detailed project plans, timelines, and budgets in order to translate scientific discoveries into innovative medical devices, therapies, and medications for FDA approval, licensing, or acquisition.

• Provide direct support for the current portfolio of strategic investment companies, focusing on the financial monitoring, budgeting, and forecasting of Novasenta, BlueSphere Bio, Avista Health, Generian, as well as other newly formed therapeutic start-ups.

• 'Own' the entire investment process, from proactively sourcing new investment opportunities and performing 'landscape' analysis, initial screening, final investment, and post-investment monitoring and support.

• Develop financial return models and perform quantitative and return analysis of companies' potential commercial pipelines in order to properly evaluate project funding proposals from UPMC and University of Pittsburgh Investigators, as well as external funding requests.

• Assess the needs of each investment project to ensure provision of UPMC's clinical, legal, and financial expertise and resources needed to ensure an efficient transition between research and clinical development.

• Master's degree, or equivalent, in Business Administration, Finance, or a related field

• Two (2) years of Healthcare, Business Development, Project Management or related experience:

o evaluating early-stage healthcare technologies for patentability, therapeutic value, and commercial potential;

o developing financial return models and performing quantitative and return analysis of companies' potential commercial pipelines;

o leading and coordinating broad diligence efforts at the evaluation stage; developing timelines, budgets, and risk-mitigation strategies in order to ensure the success of healthcare technology initiatives;

o conducting primary and secondary research and landscape analysis to assess market needs, addressable market size, competition, and regulatory and reimbursement risks;

o monitoring post-investment companies in order to provide supply chain, legal, and clinical resources, as well as external resources, such as consultants and contract research organizations (CROs).

• Telecommuting permissible 2 days a week